Family Planning Service Delivery Integration For HIV Positive And At-Risk Women In Botswana: A Hybrid Type 2 Clinical Intervention And Implementation Strategy

Overview

The goal of this pilot study is to assess both implementation outcomes (acceptability, feasibility and adoption) and clinical efficacy (contraceptive method uptake by women wishing to avoid pregnancy) using a Hybrid Type 2 study design of a family planning program being piloted by the Cervical Cancer Prevention Program in Gabarone, Botswana.

Study Type

  • Study Type: Interventional
  • Study Design
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Health Services Research
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 10, 2018

Interventions

  • Other: WHO Decision-Making Tool for Family Planning Clients and Providers
    • Contraception decision-making tool

Arms, Groups and Cohorts

  • Other: Full group
    • Our goal is to assess the feasibility and acceptability of incorporating family planning (FP) service delivery, using a program validated by the World Health Organization (WHO), into the established Cervical Cancer Prevention (CCP) programs of Botswana.

Clinical Trial Outcome Measures

Primary Measures

  • Provider acceptability rating
    • Time Frame: 6 months
    • Likert scale 1-5, rating acceptability of offering family planning in this clinical setting.
  • Provider rating of feasibility
    • Time Frame: 6 months
    • Likert scale 1-5, rating feasibility of offering family planning in this clinical setting
  • Provider report of adoption of the intervention
    • Time Frame: 6 months
    • Comparing number of family planning methods offered by a provider pre- and post-intervention

Participating in This Clinical Trial

Inclusion Criteria

1. Female

2. English or Setswana speaking

3. Receiving CCP services at the clinic

4. 18-45 years of age

5. Able to give informed consent to study procedures, as determined by research/clinic staff

Exclusion Criteria

1. Pregnant

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Pennsylvania
  • Collaborator
    • National Institute of Allergy and Infectious Diseases (NIAID)
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.